{{NoteTA
|G1=生命科学
|1=zh-hans:抑郁; zh-hk:抑鬱; zh-tw:憂鬱;
}}
{{medical}}
{{Infobox drug class
| Image    = Serotonin-2D-skeletal.svg
| Alt      =
| Caption = [[血清素|血清素]]（5-羟色胺）
| Use = [[重度抑郁症|重度抑郁症]]（MDD）<br/> [[焦虑症|焦虑症]]
| MeshID = D017367
| Consumer_Reports = antidepressants
| ATC_prefix       = N06AB 
| Drugs.com        = {{Drugs.com|drug-class|ssri-antidepressants}}
| Biological_target = [[5-羟色胺再摄取|5-羟色胺再摄取]]
}}
[[File:SSRIの作用.png|thumb]]
'''选择性5-羟色胺再摄取抑制剂'''（{{lang-en|Selective Serotonin Reuptake Inhibitor}}、[[縮寫|縮寫]]：{{Lang|en|SSRI}}），也称'''选择性血清素再摄取抑制剂'''，是一类常用的[[抗抑郁药|抗抑郁药]]，自20世纪80年代后期开始用来治疗[[抑郁症|抑郁症]]、[[焦虑症|焦虑症]]、[[强迫症|强迫症]]及[[神经性厌食症|神经性厌食症]]。此类药物过量时通常比[[三环类抗抑郁药|三环类抗抑郁药]]和[[单胺氧化酶抑制剂|单胺氧化酶抑制剂]]安全得多。

已知[[5-羟色胺|5-羟色胺]]在控制情绪时发挥着重要的作用，SSRI的作用机制是通过抑制[[突触|突触]]{{tsl|en|Neurotransmitter transporter|再摄取|再摄取泵}}对[[神经递质|神经递质]]5-羟色胺的再摄取以增加[[突触#突触的解剖结构|突触间隙]]中5-羟色胺浓度，SSRI对[[肾上腺素能受体|肾上腺素能受体]](α1，α2，β)、[[胆碱能受体|胆碱能受体]]、[[GABA受体|GABA受体]]、[[多巴胺能受体|多巴胺能受体]]（{{lang|en|dopamine transporters}}）、[[组胺受体|组胺受体]]、[[5-羟色胺受体|5-羟色胺受体]]（5HT1A， 5HT1B， 5HT2）或 [[Γ-氨基丁酸A型受体|GABA<sub>A</sub>R]]没有明显的亲和力。

常用的SSRI（前五种被誉为“抗抑郁药的五朵金花”）：
*[[氟西汀|氟西汀]]
*[[帕罗西汀|帕罗西汀]]
*[[舍曲林|舍曲林]]
*[[氟伏沙明|氟伏沙明]]
*[[西酞普兰|西酞普兰]]
*[[艾司西酞普兰|艾司西酞普兰]]

其他SSRIs：
*[[达泊西汀|达泊西汀]]（主要用于治疗[[早泄|早泄]]）
*{{tsl|en|Indalpine|吲达品}}（已停产）

{| class="wikitable" style="font-size:smaller; text-align:center"
|-
! colspan="5" | Selective serotonin reuptake inhibitors (SSRIs)
|-
| [[File:Citalopram_structure.svg|135px]]
[[西酞普兰|西酞普兰]]
| [[File:Dapoxetine_Structural_Formulae_V.1.svg|135px]]
[[达泊西汀|达泊西汀]]
| [[File:Escitalopram.svg|135px]]
[[艾司西酞普兰|艾司西酞普兰]]
| [[File:Fluoxetine-2D-skeletal.svg|135px]]
[[氟西汀|氟西汀]]
| [[File:Fluvoxamine2DACS.svg|135px]]
[[氟伏沙明|氟伏沙明]]
|-
! colspan="5" |
|-
| [[File:Indalpine.png|135px]]
{{tsl|en|Indalpine|吲达品}}
| [[File:Paroxetine-2D-skeletal.svg|135px]]
[[帕罗西汀|帕罗西汀]]
| [[File:Sertraline_Structural_Formulae.png|135px]]
[[舍曲林|舍曲林]]
| [[File:Zimelidine_Structural_Formulae_V.1.svg|135px]]
{{link-en|齐美定|Zimelidine}}
| 
|}

== 副作用 ==
=== 性功能障礙 ===
{{roughtranslation|||章節|time=2014-08-22T02:47:54+00:00}}
SSRI致性功能障碍（{{Lang|en|Post-SSRI sexual dysfunction}}、[[縮寫|縮寫]]：{{Lang|en|PSSD}}）<ref>Bahrick AS (2006). [http://www.researchgate.net/publication/236587031_Post_SSRI_Sexual_Dysfunction “Post SSRI Sexual Dysfunction”] {{Wayback|url=http://www.researchgate.net/publication/236587031_Post_SSRI_Sexual_Dysfunction |date=20140714164157 }}. ''Tablet'' 7 (3): 2-10.</ref>常見症状為：减低性欲、性无能或者[[阴道|阴道]]润滑度降低、在缺乏欲望的情况下持续性的性器官唤醒障碍、延迟或者缺乏[[性高潮|性高潮]]、对性刺激的回应缺失或者降低<ref>[http://psychrights.org/Research/Digest/AntiDepressants/PersistentSexualDysfunctionOffSSRIsCsokaetal(2007).pdf Persistent Sexual Dysfunction after Discontinuation of Selective Serotonin Reuptake Inhibitors] {{Wayback|url=http://psychrights.org/Research/Digest/AntiDepressants/PersistentSexualDysfunctionOffSSRIsCsokaetal(2007).pdf |date=20150704103718 }} ''J Sex Med'' 2008;5:227–233</ref>。初步研究发现，不到10%患者报告这种[[副作用|副作用]]。当[[医生|医生]]具体询问治疗中出现的性功能障碍時，部分醫生就患者中出現性功能障礙的比率高达60％。<ref>Zajecka J, Mitchell S, Fawcett J (1997). “Treatment-emergent changes in sexual function with selective serotonin reuptake inhibitors as measured with the Rush Sexual Inventory”. ''Psychopharmacol Bull'' 33 (4): 755–60. [http://www.ncbi.nlm.nih.gov/pubmed/9493488 PMID 9493488] {{Wayback|url=http://www.ncbi.nlm.nih.gov/pubmed/9493488 |date=20140714192035 }}</ref> 自发性报告方法被认为是导致对比有针对性的提问产生低报告率的原因，或者要么是由于对关于性功能障碍的回忆偏颇或害羞。<ref>Balon R (September 2006). [http://ajp.psychiatryonline.org/article.aspx?articleid=96978 “SSRI-associated sexual dysfunction”] {{Wayback|url=http://ajp.psychiatryonline.org/article.aspx?articleid=96978 |date=20141004202928 }}. ''Am J Psychiatry'' 163 (9): 1504–9; quiz 1664. [http://dx.doi.org/10.1176%2Fappi.ajp.163.9.1504 doi:10.1176/appi.ajp.163.9.1504]. [http://www.ncbi.nlm.nih.gov/pubmed/16946173 PMID 16946173] {{Wayback|url=http://www.ncbi.nlm.nih.gov/pubmed/16946173 |date=20140714202250 }}.</ref>

虽然性功能障碍在服用SSRIs时可能是常见的，在停药后出现持续性性功能障碍的问题不会显得那样频繁，或者至少并不像众所周知的。<ref>Bahrick AS (2008). [http://www.benthamscience.com/open/topsyj/articles/V001/42TOPSYJ.pdf “Persistence of Sexual Dysfunction Side Effects after Discontinuation of Antidepressant Medications: Emerging Evidence”] {{Wayback|url=http://www.benthamscience.com/open/topsyj/articles/V001/42TOPSYJ.pdf |date=20131019115232 }}. ''The Open Psychology Journal'' 1: 42–50 [http://dx.doi.org/10.2174%2F1874350100801010042 doi:10.2174/1874350100801010042].</ref> 性功能问题经常发生在服用SSRIs期间，或者有时在延长SSRIs的使用后，但也出现了服用SSRIs后快速出现性功能问题的报告。有些人在SSRIs类药物停药后不能恢复他们的性功能，并面临着持续的后SSRIs的性功能障碍症状。在一项研究中，SSRIs诱发的性功能障碍的病人被切换到[[多巴胺|多巴胺]]能抗抑郁药[[阿米庚酸|阿米庚酸]]，55％的病人在6个月后仍然有一些类型的性功能障碍，而单用阿米庚酸治疗的对照组只有4％。<ref>Montejo AL, Llorca G, Izquierdo JA, et al. (1999). “Sexual dysfunction with antidepressive agents. Effect of the change to amineptine in patients with sexual dysfunction secondary to SSRI“. ''Actas Esp Psiquiatr'' (in Spanish; Castilian) 27 (1): 23–34. [http://www.ncbi.nlm.nih.gov/pubmed/10380144 PMID 10380144] {{Wayback|url=http://www.ncbi.nlm.nih.gov/pubmed/10380144 |date=20140715051854 }}.</ref> 在最近的安慰剂对照的双盲研究测试SSRIs类药物用于治疗早泄的疗效，已经注意到了这些药物治疗的延缓射精的效应在一定的试验参与者的比例中可能会在停药后持续数月。<ref>Safarinejad MR, Hosseini SY (2006). “Safety and efficacy of citalopram in the treatment of premature ejaculation: a double-blind placebo-controlled, fixed dose, randomized study”. ''Int. J. Impot. Res.'' 18 (2): 164–9. [http://dx.doi.org/10.1038%2Fsj.ijir.3901384 doi:10.1038/sj.ijir.3901384]. [http://www.ncbi.nlm.nih.gov/pubmed/16107866 PMID 16107866] {{Wayback|url=http://www.ncbi.nlm.nih.gov/pubmed/16107866 |date=20140714192004 }}.</ref><ref>Arafa M, Shamloul R (2006). “Efficacy of sertraline hydrochloride in treatment of premature ejaculation: a placebo-controlled study using a validated questionnaire”. ''Int. J. Impot. Res.'' 18 (6): 534–8. [http://dx.doi.org/10.1038%2Fsj.ijir.3901469 doi:10.1038/sj.ijir.3901469]. [http://www.ncbi.nlm.nih.gov/pubmed/16554853 PMID 16554853] {{Wayback|url=http://www.ncbi.nlm.nih.gov/pubmed/16554853 |date=20140714164122 }}.</ref><ref>Safarinejad MR (October 2007). [http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=0271-0749&volume=27&issue=5&spage=444 “Safety and efficacy of escitalopram in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study”] {{Wayback|url=http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=0271-0749&volume=27&issue=5&spage=444 |date=20160408152456 }}. ''J Clin Psychopharmacol'' 27 (5): 444–50. [http://dx.doi.org/10.1097%2Fjcp.0b013e31814b98d4 doi:10.1097/jcp.0b013e31814b98d4]. [http://www.ncbi.nlm.nih.gov/pubmed/17873675 PMID 17873675] {{Wayback|url=http://www.ncbi.nlm.nih.gov/pubmed/17873675 |date=20140714221938 }}.</ref>

目前为止尚不明确何种原因导致PSSD。[[氟西汀|氟西汀]]，其中一種SSRIs類藥物，被[[人类生殖风险评估中心|人类生殖风险评估中心]]（CERHR），一个在美国国立卫生研究院环境健康科学研究所的专家小组，列为生殖毒素。<ref>Hines RN, Adams J, Buck GM, Faber W, Holson JF, Jacobson SW, Keszler M, McMartin K, Segraves RT, Singer LT, Sipes IG, Williams PL. [http://ntp.niehs.nih.gov/ntp/ohat/fluoxetine/fluoxetine_monograph.pdf NTP-CERHR Expert panel report on the reproductive and developmental toxicity of fluoxetine] {{Wayback|url=http://ntp.niehs.nih.gov/ntp/ohat/fluoxetine/fluoxetine_monograph.pdf |date=20141225173010 }}. NIH Publication No. 05-4471. 2004;1-211.</ref>

目前没有已知的对PSSD的治愈方法，很大原因是因为它的病理还很少被理解。可能的针对SSRIs导致的性功能障碍的治疗选项还只是理论上被评估。<ref>Keller Ashton A, Hamer R, Rosen RC (1997). “Serotonin reuptake inhibitor-induced sexual dysfunction and its treatment: a large-scale retrospective study of 596 psychiatric outpatients”. ''J Sex Marital Ther'' 23 (3): 165–75. [http://dx.doi.org/10.1080%2F00926239708403922 doi:10.1080/00926239708403922]. [http://www.ncbi.nlm.nih.gov/pubmed/9292832 PMID 9292832] {{Wayback|url=http://www.ncbi.nlm.nih.gov/pubmed/9292832 |date=20140715030213 }}.</ref><ref>Keltner NL, McAfee KM, Taylor CL (2002). “Mechanisms and treatments of SSRI-induced sexual dysfunction”. ''Perspect Psychiatr Care'' 38 (3): 111–6. [http://dx.doi.org/10.1111%2Fj.1744-6163.2002.tb00665.x doi:10.1111/j.1744-6163.2002.tb00665.x]. [http://www.ncbi.nlm.nih.gov/pubmed/12385082 PMID 12385082] {{Wayback|url=http://www.ncbi.nlm.nih.gov/pubmed/12385082 |date=20140715165613 }}.</ref><ref>Sukoff Rizzo SJ, Pulicicchio C, Malberg JE, et al. (September 2009). [http://journals.cambridge.org/abstract_S1461145709000406 “5-HT(1A) receptor antagonism reverses and prevents fluoxetine-induced sexual dysfunction in rats”]. ''Int. J. Neuropsychopharmacol.'' 12 (8): 1045–53. [http://dx.doi.org/10.1017%2FS1461145709000406 doi:10.1017/S1461145709000406]. [http://www.ncbi.nlm.nih.gov/pubmed/19435548 PMID 19435548] {{Wayback|url=http://www.ncbi.nlm.nih.gov/pubmed/19435548 |date=20140714232125 }}.</ref> 然而，一直缺乏对于潜在治疗方法进行随机的，[[安慰剂|安慰剂]]对照的，[[双盲|双盲]]的试验。在那些已经完成的试验中，有证据支持下列治疗策略：对于勃起障碍，增加额外的[[PDE5抑制剂|PDE5抑制剂]]比如[[西地那非|西地那非]]，对性欲降低，增加或者转换到安非他酮，对整体性的性功能障碍，转换到[[奈法唑酮|奈法唑酮]]。<ref> Balon R (2006). “SSRI-Associated Sexual Dysfunction”. ''The American Journal of Psychiatry'' 163(9).</ref>

据对精神病学家的一项调查显示，安非他酮是为SSRIs引起性功能障碍的治疗的首选药物，虽然这不是一个FDA批准的处方。36%精神科医生优选为SSRIs诱发的性功能障碍的患者转换到安非他酮，和43％的人赞成在现行的药物外增加安非他酮。<ref>Dording CM, Mischoulon D, Petersen TJ, Kornbluh R, Gordon J, Nierenberg AA, Rosenbaum JE, Fava M. (2002). [http://link.springer.com/article/10.1023/A%3A1021137118956 “The pharmacologic management of SSRI-induced side effects: a survey of psychiatrists”] {{Wayback|url=http://link.springer.com/article/10.1023/A%3A1021137118956 |date=20140903104235 }}. ''Ann Clin Psychiatry'' 14 (3): 143–7. [http://www.ncbi.nlm.nih.gov/pubmed/12585563 PMID 12585563] {{Wayback|url=http://www.ncbi.nlm.nih.gov/pubmed/12585563 |date=20140715092000 }}.</ref> 高剂量的安非他酮（最低300毫克）可能是必要的：一项随机研究以31个目标为参考，使用较低剂量（150毫克），每日一次，未能发现在安非他酮，性功能治疗或联合治疗之间的显著差异<ref>Cabello F (February 2006). [http://abstracts.co.allenpress.com/pweb/sexo2005/document/54970 “Effectiveness of the Treatment of Female Hypoactive Sexual Desire Disorder”] {{Wayback|url=http://abstracts.co.allenpress.com/pweb/sexo2005/document/54970 |date=20110911065909 }}. ''J Sex Res.'' Retrieved 2007-04-05.</ref> ，而随后的研究中有234例采用安非他酮SR150毫克，每天两次，显著改善性功能。<ref> Safarinejad M (September 2010). “The effects of the adjunctive bupropion on male sexual dysfunction induced by a selective serotonin reuptake inhibitor: a double-blind placebo-controlled and randomized study”. ''BJU International.''</ref>

其他一些标签外处方包括[[普拉克索|普拉克索]]，[[罗匹尼罗|罗匹尼罗]]，[[育亨宾|育亨宾]]和其它可能增加血液中多巴胺水平的化合物，虽然没有进行过双盲和安慰剂对照试验显示其疗效。[[卡麦角林|卡麦角林]]，即D2受体的激动剂，这反过来又降低[[催乳激素|催乳激素]]，已使得性高潮丧失受试者的三分之一完全恢复性高潮，并使得另外三分之一受试者部分恢复性高潮。<ref>{{Cite web |url=http://www.everydayhealth.com/sexual-health/0524/drug-restores-normal-orgasm-in-men.aspx |title=http://www.everydayhealth.com/sexual-health/0524/drug-restores-normal-orgasm-in-men.aspx |accessdate=2014-08-21 |archive-date=2014-08-10 |archive-url=https://web.archive.org/web/20140810123313/http://www.everydayhealth.com/sexual-health/0524/drug-restores-normal-orgasm-in-men.aspx |dead-url=no }}</ref>

绝大多数对性功能障碍的研究针对男性进行，尽管一些对妇女所做的研究显示安非他酮对其有效（剂量>300毫克/天）。已经有1研究显示使用西地那非对性高潮功能可能有益处，尽管没有性欲望或性唤醒的改变。<ref> Burghardt K (2013). “Sildenafil for SSRI-induced sexual dysfunction in women”. ''Current Psychiatry.''</ref>

== 参考文献 ==
{{Reflist}}

{{Anxiolytics}}
{{抗抑郁药}}
{{OCD pharmacotherapies}}

[[Category:选择性血清素重摄取抑制剂|Category:选择性血清素重摄取抑制剂]]
[[Category:抗抑郁药物|Category:抗抑郁药物]]